Niagen Bioscience, Inc. (NAGE) - Total Assets
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) holds total assets worth $98.14 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NAGE book value for net asset value and shareholders' equity analysis.
Niagen Bioscience, Inc. - Total Assets Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s total assets have evolved over time, based on quarterly financial data.
Niagen Bioscience, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Niagen Bioscience, Inc.'s total assets of $98.14 Million consist of 93.9% current assets and 6.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.2% |
| Accounts Receivable | $7.77 Million | 11.4% |
| Inventory | $9.19 Million | 13.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $359.00K | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NAGE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Niagen Bioscience, Inc.'s current assets represent 93.9% of total assets in 2024, a decrease from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 65.2% of total assets in 2024, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 13.5% of total assets.
Niagen Bioscience, Inc. Competitors by Total Assets
Key competitors of Niagen Bioscience, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Niagen Bioscience, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.12 | 2.95 | 1.96 |
| Quick Ratio | 3.29 | 2.35 | 1.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $70.90 Million | $34.44 Million | $15.74 Million |
Niagen Bioscience, Inc. - Advanced Valuation Insights
This section examines the relationship between Niagen Bioscience, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.80 |
| Latest Market Cap to Assets Ratio | 5.67 |
| Asset Growth Rate (YoY) | 24.2% |
| Total Assets | $68.28 Million |
| Market Capitalization | $387.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Niagen Bioscience, Inc.'s assets at a significant premium (5.67x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Niagen Bioscience, Inc.'s assets grew by 24.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual total assets of Niagen Bioscience, Inc. from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $68.28 Million | +24.22% |
| 2023-12-31 | $54.96 Million | +1.68% |
| 2022-12-31 | $54.06 Million | -6.54% |
| 2021-12-31 | $57.84 Million | +50.79% |
| 2020-12-31 | $38.36 Million | -4.69% |
| 2019-12-31 | $40.25 Million | -4.70% |
| 2018-12-31 | $42.23 Million | -32.67% |
| 2017-12-31 | $62.72 Million | +217.56% |
| 2016-12-31 | $19.75 Million | +5.35% |
| 2015-12-31 | $18.75 Million | +62.80% |
| 2014-12-31 | $11.52 Million | +28.15% |
| 2013-12-31 | $8.99 Million | -0.53% |
| 2012-12-31 | $9.03 Million | +44.09% |
| 2011-12-31 | $6.27 Million | -3.65% |
| 2010-12-31 | $6.51 Million | +82.54% |
| 2009-12-31 | $3.57 Million | -12.69% |
| 2008-12-31 | $4.08 Million | +703884.48% |
| 2007-12-31 | $580.00 | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more